Influence of ciamexon on blood glucose and insulin requirement in newly manifested type I diabetics. Results of a pilot study.
Treatment with the selectively immunomodulatory drug 1-[2-methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridine-carbonitrile (ciamexon, BM-42332), an aziridine derivative, of newly diagnosed type I diabetic patients is reported. In an open pilot study the treatment of Cx led to the independence of insulin in 33.3% of the treated patients.
Hogan
M
M
Department of Endocrinology and Metabolism, Mainz University Medical School, Fed. Rep. of Germany.
Beyer
J
J
Stuermer
W
W
Weber
P
P
Schrezenmeier
J
J
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D001323:Autoantibodies / Q000096:biosynthesis; D001388:Aziridines / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood; D055598:Chemical Phenomena; D002621:Chemistry; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism* / Q000627:therapeutic use; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000276:immunology; D008297:Male
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D001323:Autoantibodies; D001388:Aziridines; D001389:Azirines; D001786:Blood Glucose; D002096:C-Peptide; D006442:Glycated Hemoglobin; D007328:Insulin; C024211:islet cell antibody; C035520:ciamexon